Trends in the Pharmacotherapy of Nocturia, 2016-2021: Analysis of a Large Multi-Institutional Research Network
March 2023
in “
The Journal of Urology
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → Studysummary This study observed that despite the increase in nocturia cases from 2016 to 2021, the use of pharmacotherapy for the condition declined, suggesting potential undertreatment. Our plain-language summary of this paper — not a Tressless recommendation.
The study analyzed trends in the pharmacotherapy of nocturia from 2016 to 2021 using data from 508,126 adults diagnosed with nocturia. The average age of the patients was 63.2 years, with females comprising 29.9% of the population. Despite an increase in nocturia cases from 69,868 to 162,306 over the study period, the use of medications such as alpha-blockers, anticholinergics, oxybutynin, and finasteride declined. This trend suggests that nocturia may be pharmacologically undertreated in the general population. The study was supported by the Clinical Research Center of University Hospitals Cleveland Medical Center and the Case Western Reserve University Clinical and Translational Science Collaborative.
